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 ("Diabetes Mellitus"[Mesh] OR "diabetes"[All Fields]) AND ("Polychlorinated 
Biphenyls"[Mesh] OR "DDT"[Mesh] OR "Dichlorodiphenyl Dichloroethylene"[Mesh] OR 
"Hexachlorobenzene"[Mesh] OR "Hydrocarbons, Chlorinated"[Mesh] OR "Polychlorinated 
Biphenyls"[All Fields] OR “dichlorodiphenyltrichloroethane”[All Fields] OR "DDT"[All Fields] 
OR "Dichlorodiphenyl Dichloroethylene"[All Fields] OR "Hexachlorobenzene"[All Fields] OR 
“PCB”[All Fields] OR “DDE”[All Fields] OR “DDT”[All Fields] OR “HCB”[All Fields] OR 
“Pollutant”[All Fields] OR “Pesticide”[All Fields] OR “insecticide”[All Fields] OR “persistent 
organochlorine”[All Fields] OR “organochloride”[All Fields] OR “organochlorine”[All Fields] 






“Diabetes” AND ( "Polychlorinated Biphenyls" OR “dichlorodiphenyltrichloroethane” OR 
"DDT" OR "Dichlorodiphenyl Dichloroethylene" OR "Dichlorodiphenyldichloroethylene" OR 
"Hexachlorobenzene" OR “PCB” OR “DDE” OR “DDT” OR “HCB” OR “organochlorine 
Pesticide” OR “organochlorine insecticide” OR “persistent organochlorine Pollutant” OR 
“organochloride” OR “chlorocarbon” OR “chlorinated hydrocarbon” OR “chlorinated solvent”) 
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Table S1. Characteristics of study participants at baseline in 1990 by cancer status, the Nurses’ Health Study. a 
 Breast Cancer study Non-Hodgkin Lymphoma study 











Age, years 58.7 ± 6.7 58.4 ± 6.8 0.50 58.7 ± 6.5 58.8 ± 6.5 0.86 
BMI, kg/m
2
 24.7 ± 4.1 25.0 ± 4.4 0.42 25.1 ± 4.1 25.0 ± 4.3 0.85 
Smoking status, n (%)   0.57   0.64 
 Never smoked 147 (44.0) 161 (47.5)  59 (42.5) 132 (46.6)  
 Past smoker 145 (43.4) 142 (41.9)  92 (44.6) 121 (42.8)  
 Current smoker 42 (12.6) 36 (10.6)  18 (13.0) 30 (10.6)  
Alcohol drinking, n (%)   0.29   0.17 
 0g/day 62 (18.6) 59 (17.4)  29 (20.9) 83 (29.3)  
 0.1-10g/day 176 (52.7) 198 (58.4)  78 (56.1) 145 (51.2)  
 >10g/day 96 (28.7) 82 (24.2)  32 (23.0) 55 (19.4)  
Physical activity, MET-
hours/week 
16.3 ± 15.8 18.9 ± 17.2 0.04 16.5 ± 17.4 19.5 ± 38.9 0.28 
Family history of diabetes, n (%) 80 (24.0) 82 (24.2) 0.94 39 (28.1) 83 (29.3) 0.79 
Number of incident diabetes 
cases 
3 21  2 22  
Number of deaths 75 51  63 38  
Total person-years 5288 5780  2012 4867  
Incident rate of type 2 diabetes, 
case/1,000 person-years 
0.57 3.63 <0.001 0.99 4.52 0.005 
PCB118, ng/g lipid
 
 65.8 (45.8-86.2) 65.6 (47.2-85.6) 0.62 45.3 (34.1-67.0) 50.9 (34.4-78.2) 0.03 
PCB138, ng/g lipid 94.6 (67.3-133.0) 94.2 (70.6-129.9) 0.80 64.0 (46.3-83.2) 63.4 (43.8-89.3) 0.19 
PCB153, ng/g lipid 105.2 (80.2-143.6) 104.5 (80.9-140.7) 0.63 106.7 (79.5-130.8) 105.6 (79.0-141.0) 0.23 
PCB180, ng/g lipid 76.4 (56.0-100.5) 73.3 (57.1-95.1) 0.87 74.7 (57.3-89.7) 70.3 (54.4-90.1) 0.41 
∑PCBs (118,138,153,180), ng/g 
lipid 




295.8 (217.8-395.2) 0.12 
Total PCBs ng/g lipid
 b




618.9 (460.4-811.6) 0.50 
p,p’-DDT, ng/g lipid  50.6 (33.3-92.4) 57.4 (32.2-96.9) 0.23 42.9 (27.7-69.3) 44.2 (28.2-67.2) 0.18 
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HCB, ng/g lipid 28.9 (21.9-40.0) 30.4 (22.9-39.3) 0.69 35.5 (29.7-44.1) 37.2 (30.9-46.4) 0.50 
Total plasma cholesterol, mg/dL  11.8 (8.0-16.1) 11.8 (8.5-16.6) 0.77 11.7 (7.8-17.7) 12.4 (8.0-19.0) 0.10 




223.0 (191.0-246.0) 0.64 
Abbreviations: PCB, polychlorinated biphenyls; DDT, p, p’-dichlorodiphenyltrichloroethane; DDE, p, p’-
dichlorodiphenyldichloroethylene; HCB, hexachlorobenzene. 
a 
Data are mean ± SD or median (inter-quartile range) for continuous variables or % for categorical variables, unless otherwise 
indicated.
 
P values were calculated by t tests for continuous variables expressed as mean ± SD, Wilcoxon rank-sum tests for 
continuous variables expressed as median (inter-quartile range), and chi-square tests for categorical variables. 
b 




Table S2. Age-adjusted Spearman correlation coefficients between persistent organic pollutants among non-diabetic participants, the 
Nurses’ Health Study.  
 
Breast Cancer study (n=649) 
     
 





        PCB118 -0.01
NS
 
PCB138 -0.11 0.77      
PCB153 -0.21 0.80 0.89     
PCB180 -0.26 0.56 0.69 0.77    
p,p’-DDT 0.004NS 0.30 0.24 0.26 0.21   
p,p’-DDE 0.03 NS 0.42 0.47 0.49 0.40 0.15  
HCB -0.02
 NS
 0.42 0.36 0.44 0.45 0.15 0.45 
        Non-Hodgkin Lymphoma study  (n=398) 
   
 





        PCB118 0.17 
PCB138 0.001
 NS
 0.79      
PCB153 -0.10
 NS
 0.76 0.95     
PCB180 -0.20 0.53 0.70 0.83    
p,p’-DDT 0.20 0.53 0.52 0.48 0.32   
p,p’-DDE 0.07 NS 0.47 0.52 0.47 0.33 0.63  
HCB 0.03
 NS
 0.42 0.38 0.42 0.46 0.40 0.49 
NS, non-statistically significant. All correlation coefficients were adjusted for age at blood draw. P0.05 unless indicated as NS.  
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Table S3. Adjusted ORs (95% CIs) of incident diabetes per SD increment of natural log-transformed lipid-standardized plasma 
persistent organic pollutant concentrations, the Nurses’ Health Study. a 
 
 
Breast cancer study 
  
Non-Hodgkin lymphoma study 
 
Combined 
lymphoma study  Ln (POP) OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Ln HCB 
        Model 1
 b
 2.40 (0.85, 6.74) 0.10 2.53 (0.60, 10.7) 0.21 2.44 (1.05, 5.66) 0.04 
Model 2
 c
 2.11 (0.77, 5.82) 0.15  3.05 (0.70, 13.3) 0.14  2.38 (1.03, 5.48) 0.04 
Ln DDE         
Model 1
 b
 1.15 (0.65, 2.01) 0.64  0.95 (0.57, 1.61) 0.86  1.04 (0.71, 1.52) 0.85 
Model 2
 c
 1.06 (0.60, 1.86) 0.84  1.01 (0.58, 1.76) 0.97  1.03 (0.70, 1.53) 0.87 
Ln DDT         
Model 1
 b
 1.12 (0.65, 1.94) 0.68  1.15 (0.57, 2.30) 0.7  1.13 (0.74, 1.74) 0.57 
Model 2
 c
 1.09 (0.63, 1.88) 0.75  1.27 (0.61, 2.62) 0.53  1.15 (0.74, 1.78) 0.53 
Ln PCB118         
Model 1
 b
 1.87 (0.79, 4.40) 0.16  1.42 (0.66, 3.06) 0.37  1.60 (0.90, 2.84) 0.11 
Model 2
 c
 1.57 (0.65, 3.78) 0.31  1.31 (0.61, 2.82) 0.49  1.42 (0.79, 2.53) 0.24 
Ln PCB138         
Model 1
 b
 0.95 (0.39, 2.31) 0.91  0.86 (0.37, 2.00) 0.73  0.90 (0.49, 1.66) 0.74 
Model 2
 c
 0.79 (0.33, 1.93) 0.61  0.90 (0.39, 2.10) 0.81  0.85 (0.46, 1.57) 0.60 
Ln PCB153         
Model 1
 b
 2.85 (1.11, 7.33) 0.03  0.83 (0.29, 2.42) 0.73  1.66 (0.82, 3.37) 0.16 
Model 2
 c
 2.37 (0.91, 6.21) 0.08  0.87 (0.30, 2.56) 0.8  1.52 (0.74, 3.12) 0.25 
Ln PCB180         
Model 1
 b
 1.55 (0.58, 4.15) 0.38  0.75 (0.21, 2.65) 0.65  1.18 (0.54, 2.56) 0.68 
Model 2
 c
 1.45 (0.53, 3.91) 0.47  0.84 (0.24, 2.92) 0.79  1.17 (0.54, 2.54) 0.69 
Ln ∑ PCBs (118,138,153,180)        
Model 1
 b
 2.06 (0.76, 5.60) 0.16  0.95 (0.33, 2.74) 0.92  1.43 (0.69, 2.96) 0.34 
Model 2
 c
 1.72 (0.62, 4.79) 0.30  0.96 (0.34, 2.77) 0.95  1.30 (0.62, 2.71) 0.49 
Ln Total PCBs        
Model 1
 b
 1.83 (0.63, 5.33) 0.27  0.97 (0.30, 3.17) 0.96  1.37 (0.62, 3.04) 0.43 
Model 2
 c
 1.52 (0.51, 4.50) 0.45  1.02 (0.32, 3.26) 0.98  1.26 (0.57, 2.79) 0.57 
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Ln Total POPs         
Model 1
 b
 1.36 (0.53, 3.52) 0.52  1.02 (0.46, 2.30) 0.96  1.25 (0.54, 2.90) 0.61 
Model 2
 c
 1.62 (0.64, 4.13) 0.31  1.13 (0.49, 2.63) 0.78  1.55 (0.68, 3.54) 0.30 
 
Abbreviations: PCB, polychlorinated biphenyls; DDT, p, p’-dichlorodiphenyltrichloroethane; DDE, p, p’-
dichlorodiphenyldichloroethylene; HCB, hexachlorobenzene, POP, persistent organic pollutants. 
a 
ORs (95% CIs) were estimated using logistic regression. The combined results were derived using a fixed-effects model. Total PCBs 
were summed values of 22 PCB congeners in the breast cancer study and 56 PCB congeners in the non-Hodgkin lymphoma study. 
b 
Model 1: adjusted for age (years), smoking status (never/current smoker/ past smoker), alcohol intake (g/d: 0, 0.1-10 and >10), 
physical activity (MET-hours/week), family history of diabetes (yes/no), baseline BMI in 1990, total plasma cholesterol (mg/dL), 
and plasma triglyceride (mg/dL). 
c 
Model 2: further adjusted for cancer case-control status. 
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Table S4. Adjusted ORs (95% CIs) of incident diabetes according to tertiles of plasma weight-adjusted plasma persistent organic 
pollutant concentrations (ng/g plasma weight), the Nurses’ Health Study.a 
 














         
Median 0.15 0.24 0.35  0.20 0.28 0.38  
Case/control 6/330 8/161 10/158  5/206 10/96 9/96  
Model 1
 c
 1.00 3.60 (1.03, 12.6) 4.21 (1.15, 15.4) 0.03 1.00 3.91 (1.16, 13.2) 3.35 (0.91, 12.4) 0.07 
Model 2
 d
 1.00 2.68 (0.75, 9.55) 3.98 (1.10, 14.5) 0.03 1.00 4.07 (1.17, 14.1) 3.75 (0.98, 14.5) 0.06 
p,p’-DDE         
Median 2.35 5.42 10.37  2.84 6.84 14.70  
Case/control 8/216 6/219 10/214  5/135 6/135 13/128  
Model 1
 c
 1.00 0.74 (0.23, 2.37) 1.01 (0.33, 2.13) 0.92 1.00 0.79 (0.22, 2.86) 1.64 (0.51, 5.27) 0.25 
Model 2
 d
 1.00 0.62 (0.18, 2.14) 0.91 (0.29, 2.92) 0.98 1.00 0.66 (0.18, 2.51) 1.69 (0.52, 5.49) 0.19 
p,p’-DDT         
Median 0.19 0.38 0.81  0.15 0.30 0.58  
Case/control 8/216 4/221 12/212  4/136 7/134 13/128  
Model 1
 c
 1.00 0.39 (0.10, 1.46) 1.14 (0.41, 3.20) 0.47 1.00 1.11 (0.29, 4.26) 1.78 (0.50, 6.32) 0.29 
Model 2
 d
 1.00 0.42 (0.11, 1.65) 1.01 (0.35, 2.90) 0.69 1.00 0.92 (0.23, 3.64) 1.64 (0.46, 5.84) 0.30 
PCB118         
Median 0.28 0.46 0.73  0.20 0.34 0.61  
Case/control 4/220 7/218 13/211  4/136 7/134 13/128  
Model 1
 c
 1.00 2.16 (0.57, 8.11) 3.22 (0.87, 12.0) 0.09 1.00 1.47 (0.37, 5.82) 2.54 (0.65, 9.94) 0.15 
Model 2
 d
 1.00 2.22 (0.58, 8.47) 2.75 (0.72, 10.5) 0.16 1.00 1.41 (0.34, 5.80) 2.32 (0.57, 9.50) 0.21 
PCB138         
Median 0.42 0.66 1.05  0.26 0.42 0.70  
Case/control 5/219 9/216 10/214  4/136 11/130 9/132  
Model 1
 c
 1.00 1.44 (0.43, 4.87) 1.72 (0.49, 6.05) 0.42 1.00 2.01 (0.59, 6.93) 1.09 (0.28, 4.19) 0.74 
Model 2
 d
 1.00 1.44 (0.42, 4.95) 1.60 (0.45, 5.68) 0.50 1.00 2.41 (0.68, 8.58) 1.07 (0.27, 4.23) 0.64 
PCB153         
Median 0.48 0.75 1.13  0.47 0.73 1.07  





 1.00 1.92 (0.56, 6.55) 2.55 (0.68, 9.55) 0.18 1.00 1.24 (0.40, 3.87) 0.80 (0.23, 2.74) 0.63 
Model 2
 d
 1.00 1.89 (0.54, 6.61) 2.31 (0.60, 8.88) 0.25 1.00 1.31 (0.42, 4.15) 0.72 (0.20, 2.55) 0.52 
PCB180         
Median 0.35 0.52 0.76  0.34 0.49 0.69  
Case/control 7/217 9/216 8/216  9/131 5/136 10/131  
Model 1
 c
 1.00 1.36 (0.44, 4.20) 1.07 (0.28, 4.07) 0.94 1.00 0.46 (0.13, 1.62) 0.78 (0.23, 2.70) 0.86 
Model 2
 d
 1.00 1.33 (0.42, 4.26) 1.02 (0.25, 4.15) 0.98 1.00 0.44 (0.12, 1.61) 0.84 (0.23, 3.06) 0.97 
∑ PCBs (118, 138, 153, 180)       
Median 1.57 2.41 3.63  1.35 2.00 2.99  
Case/control 6/218 8/217 10/214  4/136 11/130 9/132  
Model 1
 c
 1.00 1.32 (0.40, 4.39) 1.48 (0.42, 5.29) 0.57 1.00 2.02 (0.58, 6.98) 1.20 (0.30, 4.72) 0.91 
Model 2
 d
 1.00 1.31 (0.38, 4.47) 1.41 (0.39, 5.14) 0.63 1.00 2.32 (0.65, 8.29) 1.15 (0.28, 4.70) 0.79 
Total PCBs         
Median 3.52 5.17 7.64  2.86 4.24 6.18  
Case/control 4/220 12/213 8/216  4/136 9/132 11/130  
Model 1
 c
 1.00 3.64 (1.02, 13.0) 1.53 (0.36, 6.43) 0.91 1.00 1.65 (0.45, 6.02) 1.54 (0.38, 6.23) 0.65 
Model 2
 d
 1.00 4.06 (1.08, 15.3) 1.53 (0.35, 6.58) 0.93 1.00 1.78 (0.48, 6.68) 1.44 (0.35, 6.01) 0.78 
Total POPs         
Median 7.19 11.8 18.5  6.75 12.2 21.5  
Case/control 6/218 7/218 11/213  5/135 8/133 11/130  
Model 1
 c
 1.00 1.15 (0.34, 3.88) 1.53 (0.46, 5.16) 0.47 1.00 1.02 (0.30, 3.48) 1.23 (0.36, 4.19) 0.71 
Model 2
 d
 1.00 1.00 (0.29, 3.45) 1.22 (0.35, 4.27) 0.73 1.00 0.88 (0.25, 3.13) 1.31 (0.38, 4.56) 0.56 
a 
ORs (95% CIs) were estimated using logistic regression. Total PCBs were summed values of 22 PCB congeners in the breast cancer 
study and 56 PCB congeners in the non-Hodgkin lymphoma study. 
b 
In order to include T2D cases in the lowest tertile of HCB, participants were categorized using the following cutpoints: ≤ median, 
median to 75 percentile, and ≥75 percentile.  
c
 Model 1: adjusted for age (years), smoking status (never/current smoker/ past smoker), alcohol intake (g/d: 0, 0.1-10 and >10), 
physical activity (MET-hours/week), family history of diabetes (yes/no), baseline BMI in 1990, total plasma cholesterol (mg/dL), 
and plasma triglycerides (mg/dL). 
d 
Model 2: further adjusted for cancer case-control status.  
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Table S5. Pooled adjusted ORs (95% CIs) of incident diabetes according to tertiles of plasma 
weight-adjusted plasma persistent organic pollutant concentrations (ng/g plasma weight), the 
Nurses’ Health Study. a  
 Combined 




    
Case/control 11/536 18/257 19/254  
Model 1
 c
 1.00 3.76 (1.57, 9.00) 3.76 (1.50, 9.44) 0.005 
Model 2
 d
 1.00 3.32 (1.36, 8.07) 3.87 (1.52, 9.83) 0.004 
p,p’-DDE     
Case/control 13/351 12/354 23/342  
Model 1
 c
 1.00 0.76 (0.32, 1.82) 1.25 (0.55, 2.81) 0.33 
Model 2
 d
 1.00 0.63 (0.26, 1.57) 1.24 (0.54, 2.83) 0.27 
p,p’-DDT     
Case/control 12/352 11/355 25/340  
Model 1
 c
 1.00 0.64 (0.25, 1.65) 1.31 (0.59, 2.91) 0.28 
Model 2
 d
 1.00 0.62 (0.23, 1.63) 1.21 (0.54, 2.74) 0.39 
PCB118     
Case/control 8/356 14/352 26/339  
Model 1
 c
 1.00 1.76 (0.68, 4.56) 2.77 (1.08, 7.12) 0.03 
Model 2
 d
 1.00 1.78 (0.67, 4.70) 2.52 (0.95, 6.67) 0.06 
PCB138     
Case/control 9/355 20/346 19/346  
Model 1
 c
 1.00 1.69 (0.71, 4.03) 1.37 (0.55, 3.43) 0.66 
Model 2
 d
 1.00 1.87 (0.77, 4.54) 1.35 (0.53, 3.42) 0.75 
PCB153     
Case/control 11/353 18/347 19/347  
Model 1
 c
 1.00 1.51 (0.66, 3.48) 1.35 (0.54, 3.33) 0.53 
Model 2
 d
 1.00 1.56 (0.67, 3.64) 1.26 (0.50, 3.18) 0.65 
PCB180     
Case/control 16/348 14/352 18/347  
Model 1
 c
 1.00 0.85 (0.37, 1.97) 0.89 (0.36, 2.22) 0.93 
Model 2
 d
 1.00 0.83 (0.35, 1.96) 0.94 (0.36, 2.43) 0.97 
∑ PCBs (118, 138, 153, 180)    
Case/control 10/354 19/347 19/347  
Model 1
 c
 1.00 1.62 (0.68, 3.82) 1.31 (0.51, 3.33) 0.75 
Model 2
 d
 1.00 1.76 (0.73, 4.26) 1.29 (0.50, 3.37) 0.83 
Total PCBs     
Case/control 8/356 21/345 19/346  
Model 1
 c
 1.00 2.37 (0.96, 5.83) 1.47 (0.54, 4.00) 0.77 
Model 2
 d
 1.00 2.60 (1.03, 6.57) 1.45 (0.52, 4.03) 0.82 
Total POPs     
Case/control 11/353 15/351 22/343  
Model 1
 c
 1.00 1.08 (0.45, 2.57) 1.36 (0.58, 3.22) 0.47 
Model 2
 d




ORs (95% CIs) were estimated using logistic regression. The combined results were derived 
using a fixed-effects model. Total PCBs were summed values of 22 PCB congeners in the 
breast cancer study and 56 PCB congeners in the non-Hodgkin lymphoma study. 
b 
In order to include T2D cases in the lowest tertile of HCB, participants were categorized using 
the following cutpoints: ≤ median, median to 75 percentile, and ≥75 percentile.  
c
 Model 1: adjusted for age (years), smoking status (never/current smoker/ past smoker), alcohol 
intake (g/d: 0, 0.1-10 and >10), physical activity (MET-hours/week), family history of diabetes 
(yes/no), baseline BMI in 1990, total plasma cholesterol (mg/dL), and plasma triglycerides 
(mg/dL). 
d 





Table S6. Adjusted ORs (95% CIs) of incident diabetes according to tertiles of lipid-standardized 
plasma persistent organic pollutant concentrations (ng/g lipids), the Nurses’ Health Study.a 
 
 Pooled datasets of breast cancer study and non-Hodgkin 
lymphoma study  
POP  Tertile 1 Tertile 2 Tertile 3 P for trend 
HCB  
    Case/control  8/349 17/349 23/349 
Model 1
 b
  1.00 2.14 (0.86, 5.32) 3.79 (1.54, 9.34) 0.003 
Model 2
 c
  1.00 1.89 (0.75, 4.79) 3.35 (1.34, 8.37) 0.007 
p,p’-DDE   
    Case/control  11/349 19/349 18/349 
Model 1
 b
  1.00 1.67 (0.76, 3.65) 1.47 (0.65, 3.29) 0.39 
Model 2
 c
  1.00 1.53 (0.68, 3.43) 1.51 (0.66, 3.44) 0.35 
p,p’-DDT  
    Case/control  14/349 15/349 19/349 
Model 1
 b
  1.00 0.92 (0.42, 1.98) 1.03 (0.49, 2.18) 0.93 
Model 2
 c
  1.00 0.98 (0.45, 2.16) 1.06 (0.49, 2.27) 0.88 
PCB118  
    Case/control  11/349 17/349 20/349 
Model 1
 b
  1.00 1.52 (0.67, 3.45) 1.66 (0.73, 3.77) 0.24 
Model 2
 c
  1.00 1.50 (0.65, 3.47) 1.58 (0.68, 3.64) 0.31 
PCB138  
    Case/control  15/349 17/349 16/349 
Model 1
 b
  1.00 1.06 (0.51, 2.23) 1.12 (0.53, 2.40) 0.76 
Model 2
 c
  1.00 1.04 (0.49, 2.23) 1.07 (0.49, 2.34) 0.86 
PCB153  
    Case/control  15/349 17/349 16/349 
Model 1
 b
  1.00 1.13 (0.53, 2.41) 1.44 (0.66, 3.15) 0.37 
Model 2
 c
  1.00 1.16 (0.54, 2.53) 1.39 (0.62, 3.11) 0.42 
PCB180  
    Case/control  17/349 19/349 12/349 
Model 1
 b
  1.00 1.49 (0.72, 3.07) 1.23 (0.53, 2.86) 0.56 
Model 2
 c
  1.00 1.46 (0.69, 3.08) 1.33 (0.56, 3.17) 0.48 
∑ PCBs (118,138,153,180)    
Case/control  15/349 17/349 16/349  
Model 1
 b
  1.00 1.13 (0.54, 2.39) 1.20 (0.55, 2.59) 0.65 
Model 2
 c
  1.00 1.14 (0.53, 2.45) 1.19 (0.54, 2.63) 0.66 
Total PCBs  
    Case/control  15/349 17/349 16/349 
Model 1
 b
  1.00 1.23 (0.58, 2.60) 1.24 (0.57, 2.70) 0.58 
Model 2
 c
  1.00 1.41 (0.65, 3.04) 1.24 (0.56, 2.76) 0.59 
Total POPs      
Case/control  11/349 16/349 21/349  
Model 1
 b
  1.00 1.55 (0.69, 3.49) 2.01 (0.91, 4.44) 0.09 
Model 2
 c




ORs (95% CIs) were estimated using logistic regression. Before pooling individual-level data of 
the non-Hodgkin lymphoma and breast cancer studies, within each dataset, a standardized score 
of each persistent organic pollutant was computed by using Rosner’s non-parametric approach, 
the derived scores were then used to represent its distribution. Total PCBs were summed values 
of 22 PCB congeners in the breast cancer study and 56 PCB congeners in the non-Hodgkin 
lymphoma study. 
b 
Model 1: adjusted for age (years), smoking status (never/current smoker/ past smoker), alcohol 
intake (g/d: 0, 0.1-10 and >10), physical activity (MET-hours/week), family history of diabetes 
(yes/no), baseline BMI in 1990, and data source (breast cancer study/ non-Hodgkin lymphoma 
study). 
c 
Model 2: further adjusted for cancer case-control status.
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Table S7. Adjusted ORs (95% CIs) of incident diabetes according to tertiles of lipid-standardized 
plasma persistent organic pollutant concentrations (ng/g lipids) among cancer free participants, 
the Nurses’ Health Study. a 
 
 Combined datasets of breast cancer study and non-
Hodgkin lymphoma study  
POP  Tertile 1 Tertile 2 Tertile 3 P for trend 
HCB  
    Case/control  10/193 13/193 20/193 
Model 1
 b
  1.00 1.10 (0.43, 2.80) 2.47 (1.02, 5.99) 0.03 
DDE      
Case/control  9/193 17/193 17/193  
Model 1
 b
  1.00 1.78 (0.74, 4.30) 1.85 (0.77, 4.49) 0.19 
DDT      
Case/control  12/193 14/193 17/193  
Model 1
 b
  1.00 1.07 (0.46, 2.46) 1.15 (0.51, 2.59) 0.74 
PCB118      
Case/control  10/193 15/193 18/193  
Model 1
 b
  1.00 1.35 (0.56, 3.26) 1.46 (0.61, 3.53) 0.41 
PCB138      
Case/control  15/193 15/193 14/193  
Model 1
 b
  1.00 0.87 (0.39, 1.95) 0.93 (0.41, 2.09) 0.85 
PCB153      
Case/control  14/193 15/193 14/193  
Model 1
 b
  1.00 1.04 (0.46, 2.36) 1.28 (0.54, 3.01) 0.58 
PCB180      
Case/control  16/193 14/193 13/193  
Model 1
 b
  1.00 1.20 (0.53, 2.73) 1.41 (0.58, 3.44) 0.45 
∑ PCBs (118,138,153,180)    
Case/control  14/193 15/193 14/193  
Model 1
 b
  1.00 1.05 (0.47, 2.35) 1.06 (0.46, 2.48) 0.89 
Total PCBs      
Case/control  12/193 18/193 13/193  
Model 1
 b
  1.00 1.66 (0.73, 3.76) 1.20 (0.49, 2.92) 0.74 
Total POPs      
Case/control  9/193 16/193 18/193  
Model 1
 b
  1.00 1.88 (0.77, 4.58) 2.12 (0.87, 5.13) 0.11 
a 
ORs (95% CIs) were estimated using logistic regression. Before combining individual-level 
data from the non-Hodgkin lymphoma and breast cancer studies, within each dataset, a 
standardized score of each persistent organic pollutant was computed by using Rosner’s non-
parametric approach. The derived scores were then used to represent its distribution. Total 
PCBs were summed values of 22 PCB congeners in the breast cancer study and 56 PCB 
congeners in the non-Hodgkin lymphoma study. 
b
Model 1: adjusted for age (years), smoking status (never/current smoker/ past smoker), alcohol 
intake (g/d: 0, 0.1-10 and >10), physical activity (MET-hours/week), family history of diabetes 





Figure S1. Dose-response relationship between concentrations of total PCBs and risk of type 2 
diabetes in prospective studies. Solid line represents point estimates of association between total 
PCBs and diabetes risk, derived by using generalized least-squares method for trend estimation 
of summarized dose-response data; dashed lines are 95% CI of the point estimates. Filled blue 
circles and red circles are odds ratios corresponding to comparison categories in the breast cancer 
study and non-Hodgkin lymphoma study, respectively. The open circles are odds ratios from 
other contributing prospective studies (grey lines from top to bottom are Lee et al. 2011; Turyk 
et al. 2009; men and women in Vasiliu et al. 2006). Yucheng cohort (Wang et al. 2008) was 
excluded from this the dose-response analysis because this study included subjects who were 
poisoned by exposure to extraordinarily-high levels of PCBs and polychlorinated dibenzofurans 
(PCDFs) in contaminated cooking oil. 
 
